Skip to main content
main-content

Free registration

Medicine Matters is developed for healthcare professionals as

a premier resource for the latest clinical information in medicine.

Editor's pick

12-07-2019 | Rheumatoid arthritis | Highlight | News

SELECT COMPARE: Upadacitinib outperforms placebo and adalimumab in RA

Rheumatoid arthritis patients treated with the JAK1 selective inhibitor upadacitinib experience greater improvement in the signs and symptoms of disease than those given placebo or adalimumab, indicate findings from the SELECT COMPARE trial.

15-07-2019 | Rheumatoid arthritis | View from the clinic | Article

JAK inhibitors in rheumatoid arthritis

Peter Taylor outlines the pharmacology of JAK inhibitors, and discusses their efficacy and safety profiles in patients with rheumatoid arthritis.

10-07-2019 | Psoriatic arthritis | Highlight | Article

Methotrexate versus etanercept as first-line therapy for psoriatic arthritis

William Tillett, Deepak Jadon, and Jobie Evans debate the clinical reasons relating to the efficacy, safety, and practicality of using etanercept or methotrexate as first-line therapy for psoriatic arthritis.

Latest from across the site

19-07-2019 | Gout | News

Genetic loci influencing asymptomatic hyperuricemia to gout progression identified

A Japanese genome-wide association study has identified novel genetic loci associated with the susceptibility of gout in individuals with asymptomatic hyperuricemia.

18-07-2019 | Rheumatoid arthritis | News

Surrogate randomization technique enables triple biologic comparison

Estimated remission and retention rates do not differ significantly among patients with rheumatoid arthritis treated with either certolizumab pegol, abatacept, or biosimilar infliximab, show the results of a surrogate randomized controlled trial.

17-07-2019 | Axial spondyloarthritis | News

Mild tapering of TNF inhibitors may be appropriate in axSpA

Real-world study results suggest that mild tapering of tumor necrosis factor inhibitors does not influence the probability of achieving inactive disease among patients with axial spondyloarthritis.

15-07-2019 | Rheumatoid arthritis | View from the clinic | Article

JAK inhibitors in rheumatoid arthritis

Peter Taylor outlines the pharmacology of JAK inhibitors, and discusses their efficacy and safety profiles in patients with rheumatoid arthritis.

15-07-2019 | Osteoarthritis | News

Vitamin D has potential benefits for people with osteoarthritis

Vitamin D intake is inversely associated with cartilage degeneration among patients with osteoarthritis, and supplementation may have a protective effect, suggests an analysis of data from the Osteoarthritis Initiative.

12-07-2019 | Rheumatoid arthritis | Highlight | News

SELECT COMPARE: Upadacitinib outperforms placebo and adalimumab in RA

Rheumatoid arthritis patients treated with the JAK1 selective inhibitor upadacitinib experience greater improvement in the signs and symptoms of disease than those given placebo or adalimumab, indicate findings from the SELECT COMPARE trial.

Latest from us on Twitter

Trending this week

Meet our Editorial Board

New Content Item Meet our Advisory Board

Image Credits